I think the market doesn't understand that Tryp isn't competing directly with those other companies as its delivery technology is what should propel it into being the leading company for the use of this substance for medical practitioners. Using psilocybin, as a therapeutic, can only be done safely imo by intravenous injections, all the other ways of administering it is just too risky and takes too long for it to be a viable option for the myriads of neurological diseases that this compound has shown to be profoundly beneficial in helping.
I believe company's market cap will reflect this in due course.
TYP Price at posting:
2.4¢ Sentiment: Buy Disclosure: Held
